They generally improve cardiovascular outcomes and have a low risk of causing hypoglycemia compared to other diabetes medications
However, individual responses vary, so ongoing monitoring of hormone levels and potential adverse effects is essential
To test whether the incretin hormone GLP-1 was the predominant contributor to the observed improvement of glucose homeostasis, we employed exendin 939 (Ex-9), a GLP-1 receptor antagonist
sample stability in storage, formulation, and assay medium
It encodes MOTS-c, a 16-amino-acid peptide that travels from the mitochondrial matrix into the nucleus and even into the bloodstream, acting less like a local signaling molecule and more like a systemic hormone
Your body begins adapting to GLP-1, GIP, and glucagon receptor activation simultaneously